Primärer Hyperparathyreoidismus – Diagnostik und Therapie

Der primäre Hyperparathyreoidismus ist eine häufige Ursache der Hyperkalziämie. Oft bleibt das Krankheitsbild über Jahre unerkannt. Während es milde Verläufe gibt, treten doch häufig erhebliche Organschäden auf, und es kann sogar zu lebensbedrohlichen Zuständen kommen. Dieser Artikel gibt einen Überblick über die notwendige Diagnostik bei primärem Hyperparathyreoidismus, über wichtige Differenzialdiagnosen und über die verschiedenen Therapieoptionen.

• Literatur

• 1 Bilezikian JP, Brandi ML, Rubin M. et al. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med 2005; 257: 6-17
• 2 Yanevskaya LG, Karonova T, Sleptsov IV. et al. Clinical phenotypes of primary hyperparathyroidism in hospitalized patients who underwent parathyroidectomy. Endocr Connect 2021; 10: 248-255
• 3 Andersson P, Rydberg E, Willenheimer R.. Primary hyperparathyroidism and heart disease? A review. Eur Heart J 2004; 25: 1776-1787
• 4 Zheng M-H, Li F-X-Z, Xu F. et al. The interplay between the renin-angiotensin-aldosterone system and parathyroid hormone. Front Endocrinol 2020; 11: 539
• 5 Pepe J, Cipriani C, Sonato C. et al. Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur J Endocrinol 2017; 177: R297-R308
• 6 Bilezikian JP, Cusano NE, Khan AA. et al. Primary hyperparathyroidism. Nat Rev Dis Primer 2016; 2: 16033
• 7 Sharretts JM, Simonds WF.. Clinical and molecular genetics of parathyroid neoplasms. Best Pract Res Clin Endocrinol Metab 2010; 24: 491-502
• 8 Bilezikian JP, Khan AA, Silverberg SJ. et al. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the Fifth International Workshop. J Bone Miner Res Off J Am Soc Bone Miner Res 2022; 37: 2293-2314
• 9 Gollisch K, Siggelkow H.. Asymptomatischer primärer Hyperparathyreoidismus: operieren oder beobachten. Internist 2021; 62: 496-504
• 10 Cipriani C, Biamonte F, Costa AG. et al. Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology. J Clin Endocrinol Metab 2015; 100: 1309-1315
• 11 Ejlsmark-Svensson H, Rolighed L, Harsløf T. et al. Risk of fractures in primary hyperparathyroidism: a systematic review and meta-analysis. Osteoporos Int 2021; 32: 1053-1060
• 12 Fisher SB, Perrier ND.. Primary hyperparathyroidism and hypertension. Gland Surg 2020; 9: 142-149
• 13 Eastell R, Brandi ML, Costa AG. et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99: 3570-3579
• 14 Orr LE, Zhou H, Zhu CY. et al. Skeletal effects of combined medical and surgical management of primary hyperparathyroidism. Surgery 2020; 167: 144-148
• 15 Miyaoka D, Imanishi Y, Kato E. et al. Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism. Endocrine 2020; 69: 1-8
• 16 Nasiri S, Soroush A, Hashemi AP. et al. Parathyroid adenoma Localization. Med J Islam Repub Iran 2012; 26: 103-109
• 17 Kluijfhout WP, Pasternak JD, Drake FT. et al. Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. Langenbecks Arch Surg 2016; 401: 925-935
• 18 Walker MD, Silverberg SJ.. Primary hyperparathyroidism. Nat Rev Endocrinol 2018; 14: 115-125
• 19 Abdulla AG, Ituarte PHG, Harari A. et al. Trends in the frequency and quality of parathyroid surgery: analysis of 17,082 cases over 10 years. Ann Surg 2015; 261: 746-750
• 20 Cesareo R, Di Stasio E, Vescini F. et al. Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 2015; 26: 1295-1302